The Diagnostic Imaging mammography modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of mammography, including 2D digital mammography, digital breast tomosynthesis, and breast ultrasound.
July 24th 2024
Intended for mammography and digital breast tomosynthesis (DBT) interpretation, the device reportedly emphasizes high-definition image quality and ease of use for radiologists.
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
Study Suggests the COVID-19 Pandemic Led to Millions of Decreased Cancer Screenings
June 6th 2022A new survey study from the American Cancer Society shows a 4.47 million decrease in cervical cancer screenings and a 2.13 million decrease in breast cancer screenings in the United States between 2018 and 2020.
Is Digital Breast Tomosynthesis Superior to Digital Mammography?
May 23rd 2022A closer look at the literature suggests the combination of digital breast tomosynthesis (DBT) and two-dimensional (2D) digital mammography (DM) has relatively equivalent cancer detection rates as using DM alone, according to a recent presentation at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) conference.
New Study Points to Longer Duration of Axillary Lymphadenopathy After COVID-19 Vaccine
May 20th 2022While COVID-19 vaccine clinical trials noted that post-vaccine axillary lymphadenopathy lasted for one to 10 days, emerging breast ultrasound research found a mean resolution of 127 days after a first vaccine dose.
Can AI-Powered Mammography Screening be a Game Changer?
April 25th 2022In a retrospective study involving mammography screening in over 114,000 women, researchers found that an artificial intelligence model had comparable specificity and sensitivity to radiologist screenings, reduced false positive results by 25 percent and reduced radiologist workload by more than 62 percent.
'A Call to Arms' for Electronic Transfer of Medical Images Between Institutions
April 12th 2022In a recent video interview, Arun Krishnaraj, MD, MPH and David Larson, MD, MBA, discussed the continued use of physical media to transport medical images between different health-care facilities, resulting inefficiencies and delays with patient care, and the initiative to create a linked multi-hub model to end this dated practice once and for all.
New Review Reveals Flaws of Influential Canadian RCTs on Mammography Screening
March 29th 2022A closer look at the Canadian National Breast Screening Studies (CNBSS) has revealed key methodological flaws that may prohibit use of the findings in the development of future guidelines on mammography screening for breast cancer.
Reinvigorating Breast Cancer Screening Efforts in Local Communities
March 24th 2022Discussing personal, practical and technological challenges that may thwart breast cancer screening, this author says increased sensitivity, advances in mammography imaging and creative awareness-raising alliances can make a difference in communities big and small.
Study Offers Closer Look at AI-Enabled Tool for Assessing Breast Density
March 21st 2022The artificial intelligence (AI) model reportedly had an 89.3 accuracy rate in differentiating between non-dense and dense breasts on mammography scans, and a 90.4 percent rate of agreement with human radiologist reviewers.
Study Shows Link Between Breast Arterial Calcification and Significant Cardiovascular Risks
March 18th 2022While breast arterial calcification is a common incidental finding on mammograms that is not routinely recommended for follow-up, statistically significant associations with cardiovascular risks may change that approach for postmenopausal women.
Breast Imaging: Challenges and Opportunities in the Aftermath of the COVID-19 Pandemic
March 8th 2022In a recent video interview, Amy K. Patel, MD, discussed the aftereffects of delayed breast cancer screening due to the COVID-19 pandemic, keys for improving outreach to underserved communities, legislative wins and challenges, and coalition building to educate and encourage women to resume regular breast cancer screening exams.
Study Suggests Overdiagnosis in More Than 15 Percent of Mammography-Detected Breast Cancer Cases
March 4th 2022In a large study reviewing biennial mammography screening for women between the ages of 50 to 74, researchers estimated a 6.1 percent overdiagnosis rate for indolent pre-clinical cancer and a 9.3 percent overdiagnosis rate for progressive pre-clinical cancer in women who would have died from other causes prior to clinical diagnosis.